Wisevoter
U.S.

Cantor Fitzgerald Issues Bullish Rating for Arcutis

The investment firm initiated coverage on Arcutis Biotherapeutics with an Overweight rating and a $48 price forecast.

Updated on Oct. 15, 2026 in Biotech

Bold flat-color editorial illustration featuring a geometric cream jar in navy and cream, symbolizing pharmaceutical market growth.
Cantor Fitzgerald initiated coverage on Arcutis Biotherapeutics with an Overweight rating, projecting robust sales for its dermatology treatment, Zoryve. AI Illustration. Upload story photo >

Live Poll

Is now a good time for individual investors to consider buying shares in pharmaceutical companies?

Cantor Fitzgerald initiated coverage of Arcutis Biotherapeutics with an Overweight rating, citing the strong market performance of the company's dermatology product, Zoryve. Following the announcement, shares of Arcutis Biotherapeutics increased 8.77 percent to $28.72.

Why it matters

Analysts at Cantor Fitzgerald highlighted robust Zoryve sales and competitive advantages over rival treatments, such as Incyte Corporation's Opzelura. They pointed to the lack of restrictive boxed warnings for Zoryve as a key factor supporting its growth in the dermatology market.

Zoryve net product sales reached $129.9 million in the second quarter of 2026, representing 59 percent growth year over year and 23 percent sequentially. The product is marketed as a once-daily, nonsteroidal treatment.

The players

Arcutis Biotherapeutics

This biopharmaceutical company focuses on developing and commercializing dermatological treatments for inflammatory skin conditions.

Cantor Fitzgerald

This financial services firm provides investment banking, capital markets, and equity research services to clients worldwide.

Incyte Corporation

This biopharmaceutical company specializes in discovering and developing proprietary therapeutics for oncology and dermatology.

The details

Arcutis Biotherapeutics has secured seven FDA approvals since 2022, including the June 2026 clearance for Zoryve cream 0.3 percent in children as young as 2. Cantor Fitzgerald analysts project the treatment could reach peak sales between $2.6 billion and $3.5 billion as it competes for market share against branded alternatives like Opzelura.

Timeline

  1. 2022: Start of the company's ongoing period of seven FDA product approvals.

  2. June 2026: The FDA approved Zoryve cream 0.3 percent for children aged 2 and older.

  3. Q2 2026: Arcutis reported $129.9 million in net product sales for Zoryve.

  4. October 15, 2026: Cantor Fitzgerald initiated its coverage of Arcutis Biotherapeutics.

  5. February 23, 2027: The FDA is scheduled to decide on Zoryve cream 0.05 percent for infants.

The Tech Race

This development highlights the ongoing competition in the dermatology sector between nonsteroidal treatments and existing therapies like Opzelura. By avoiding restrictive safety warnings, Arcutis aims to challenge established products and capture a larger share of the topical market.

Patients and healthcare providers may see increased availability of Zoryve as the manufacturer pursues new indications for younger populations. These financial projections reflect the potential for broader insurance coverage and market access for patients managing inflammatory skin conditions.

The takeaway

Investment analyst ratings often signal shifting market sentiment based on revenue growth and regulatory status. Patients and investors should note that future product expansions, such as the potential infant indication, remain subject to pending regulatory review.

What happens next

The FDA is scheduled to reach a decision regarding the approval of Zoryve cream 0.05 percent for infants by February 23, 2027.

Further reading

For more on the latest developments in the industry, visit the Biotech section.

Source note: This article includes information reported by Benzinga.

Live Poll

Is now a good time for individual investors to consider buying shares in pharmaceutical companies?